Olezarsen
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 99 publications
Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.
Journal: Journal of comparative effectiveness research
Published: June 19, 2026
Olezarsen for Hypertriglyceridemia: A New Therapy Update with Systematic Review and Meta-Analysis.
Journal: Cardiology in review
Published: June 16, 2026
ApoC[III] You Later: A Review of Plozasiran for the Management of Familial Chylomicronemia Syndrome.
ApoC[III] You Later: A Review of Plozasiran for the Management of Familial Chylomicronemia Syndrome.
Journal: The Annals of pharmacotherapy
Published: June 06, 2026
Translating Lipoprotein Genetics Into New Therapies.
Journal: Circulation research
Published: June 04, 2026
Olezarsen for Hypertriglyceridemia and Pancreatitis Risk. Reply.
Journal: The New England journal of medicine
Published: April 29, 2026
Olezarsen for Hypertriglyceridemia and Pancreatitis Risk.
Journal: The New England journal of medicine
Published: April 29, 2026
Olezarsen for Hypertriglyceridemia and Pancreatitis Risk.
Journal: The New England journal of medicine
Published: April 29, 2026
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference.
Journal: Current atherosclerosis reports
Published: April 24, 2026
Trimming the Fat: How Olezarsen Is Poised to Transform the Management of Severe Hypertriglyceridemia-Induced Acute Pancreatitis.
Journal: Digestive diseases and sciences
Published: April 18, 2026
Plozasiran (Redemplo) for familial chylomicronemia syndrome.
Journal: The Medical letter on drugs and therapeutics
Published: April 10, 2026
Oligonucleotides: Evolution of Carcinogenicity and Risk Assessment Strategy.
Journal: Toxicologic pathology
Published: March 31, 2026
Last Updated: 06/30/2026